Null Results in Brief
Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associations—An Extensive Replication of the Associations from the Candidate Gene Era
Alessandro Martino, Daniele Campa, Artur Jurczyszyn, Joaquín Martínez-López, María José Moreno, Judit Varkonyi, Charles Dumontet, Ramón García-Sanz, Federica Gemignani, Krzysztof Jamroziak, Anna Stępień, Svend E. Hove Jacobsen, Vibeke Andersen, Manuel Jurado, Stefano Landi, Anna Maria Rossi, Fabienne Lesueur, Herlander Marques, Marek Dudziński, Marzena Wątek, Victor Moreno, Enrico Orciuolo, Mario Petrini, Rui Manuel Reis, Rafael Ríos, Juan Sainz, Ulla Vogel, Gabriele Buda, Annette Juul Vangsted and Federico Canzian
Alessandro Martino
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Daniele Campa
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Artur Jurczyszyn
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Joaquín Martínez-López
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
María José Moreno
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Judit Varkonyi
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Charles Dumontet
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Ramón García-Sanz
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Federica Gemignani
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Krzysztof Jamroziak
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Anna Stępień
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Svend E. Hove Jacobsen
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Vibeke Andersen
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Manuel Jurado
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Stefano Landi
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Anna Maria Rossi
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Fabienne Lesueur
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Herlander Marques
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Marek Dudziński
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Marzena Wątek
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Victor Moreno
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Enrico Orciuolo
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Mario Petrini
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Rui Manuel Reis
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Rafael Ríos
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Juan Sainz
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Ulla Vogel
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Gabriele Buda
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Annette Juul Vangsted
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
Federico Canzian
1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
DOI: 10.1158/1055-9965.EPI-13-1115 Published April 2014
Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 23, Issue 4, pp. 670-674
PubMed
Published By
Print ISSN
Online ISSN
History
- Received October 23, 2013
- Revision received December 3, 2013
- Accepted February 4, 2014
- Published first February 12, 2014.
Article Versions
- Previous version (February 12, 2014 - 07:01).
- Previous version (March 11, 2014 - 06:20).
- You are viewing the most recent version of this article.
Copyright & Usage
©2014 American Association for Cancer Research.
Author Information
- Alessandro Martino1,
- Daniele Campa2,
- Artur Jurczyszyn3,
- Joaquín Martínez-López8,
- María José Moreno9,
- Judit Varkonyi14,
- Charles Dumontet15,
- Ramón García-Sanz10,
- Federica Gemignani17,
- Krzysztof Jamroziak4,
- Anna Stępień5,
- Svend E. Hove Jacobsen18,
- Vibeke Andersen19,20,
- Manuel Jurado11,12,
- Stefano Landi17,
- Anna Maria Rossi17,
- Fabienne Lesueur16,
- Herlander Marques23,24,
- Marek Dudziński6,
- Marzena Wątek7,
- Victor Moreno13,
- Enrico Orciuolo25,
- Mario Petrini25,
- Rui Manuel Reis23,24,26,
- Rafael Ríos11,12,
- Juan Sainz11,12,
- Ulla Vogel21,
- Gabriele Buda25,
- Annette Juul Vangsted22, and
- Federico Canzian1
- Authors' Affiliations: 1Genomic Epidemiology Group, 2Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Hematology, Cracow University Hospital, Cracow; 4Medical University of Łodz; 5Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Łodz; 6Rzeszow Regional Hospital, Rzeszow; 7Holycross Cancer Center, Kielce, Poland; 8Department of Hematology, Hospital Universitario Doce de Octubre, Madrid; 9Morales Meseguer General University Hospital, Murcia; 10University Hospital of Salamanca, Salamanca; 11Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government; 12Hematology Department, Virgen de las Nieves University Hospital, Granada; 13IDIBELL—Catalan Institute of Oncology, University of Barcelona, Barcelona, Spain; 14Semmelweis University, Budapest, Hungary; 15Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Université Claude Bernard Lyon I, Lyon; 16Genetic Epidemiology of Cancer team, INSERM, U900, Institut Curie, Mines ParisTech, Paris, France; 17Department of Biology, University of Pisa, Pisa, Italy; 18Clinic of Immunology, Laboratory Center, Hospital of Southern Jutland, Sønderborg; 19Organ Center, Hospital of Southern Jutland, Aabenraa; 20Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense C; 21National Research Centre for the Working Environment, Copenhagen; 22Roskilde Hospital, Copenhagen University, Roskilde, Denmark; 23Life and Health Sciences Research Institute, University of Minho, Braga; 24ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 25UO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy; and 26Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
- Corresponding Author:
Federico Canzian, German Cancer Research Center (DKFZ), Genomic Epidemiology Group, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany. Phone: 49-6221-42-1791; Fax: 49-6221-42-1810; E-mail: f.canzian{at}dkfz.de
A. Martino and D. Campa contributed equally to this work.
April 2014
Volume 23, Issue 4
Volume 23, Issue 4
Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associations—An Extensive Replication of the Associations from the Candidate Gene Era
Alessandro Martino, Daniele Campa, Artur Jurczyszyn, Joaquín Martínez-López, María José Moreno, Judit Varkonyi, Charles Dumontet, Ramón García-Sanz, Federica Gemignani, Krzysztof Jamroziak, Anna Stępień, Svend E. Hove Jacobsen, Vibeke Andersen, Manuel Jurado, Stefano Landi, Anna Maria Rossi, Fabienne Lesueur, Herlander Marques, Marek Dudziński, Marzena Wątek, Victor Moreno, Enrico Orciuolo, Mario Petrini, Rui Manuel Reis, Rafael Ríos, Juan Sainz, Ulla Vogel, Gabriele Buda, Annette Juul Vangsted and Federico Canzian
Cancer Epidemiol Biomarkers Prev April 1 2014 (23) (4) 670-674; DOI: 10.1158/1055-9965.EPI-13-1115
Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associations—An Extensive Replication of the Associations from the Candidate Gene Era
Alessandro Martino, Daniele Campa, Artur Jurczyszyn, Joaquín Martínez-López, María José Moreno, Judit Varkonyi, Charles Dumontet, Ramón García-Sanz, Federica Gemignani, Krzysztof Jamroziak, Anna Stępień, Svend E. Hove Jacobsen, Vibeke Andersen, Manuel Jurado, Stefano Landi, Anna Maria Rossi, Fabienne Lesueur, Herlander Marques, Marek Dudziński, Marzena Wątek, Victor Moreno, Enrico Orciuolo, Mario Petrini, Rui Manuel Reis, Rafael Ríos, Juan Sainz, Ulla Vogel, Gabriele Buda, Annette Juul Vangsted and Federico Canzian
Cancer Epidemiol Biomarkers Prev April 1 2014 (23) (4) 670-674; DOI: 10.1158/1055-9965.EPI-13-1115
Jump to section
Advertisement